Search





Search





Markets
/
Stocks
/
nasdaq-acon
/

Aclarion Inc

ACON

Add to Watchlist

3.160USD

-0.060-1.86%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

7.73MMarket Cap

LossP/E TTM



Aclarion Inc

3.160

-0.060-1.86%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aclarion Inc

Currency: USD Updated: 2026-05-15

Key Insights

Aclarion Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 196 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aclarion Inc's Score

Industry at a Glance

Industry Ranking

196 / 382

Overall Ranking

379 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Aclarion Inc Highlights

StrengthsRisks

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Growing

The company is in a growing phase, with the latest annual income totaling USD 75.73K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 75.73K.

Undervalued

The company’s latest PE is -0.56, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 58.05K shares, increasing 22.32% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 6.78K shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

7.000

Target Price

+117.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Aclarion Inc is 6.57, ranking 228 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 21.14K, representing a year-over-year increase of 11.32%, while its net profit experienced a year-over-year increase of 39.60%.

Score

Industry at a Glance

Previous score

6.57

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.21

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.73

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Aclarion Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Aclarion Inc is 6.52, ranking 248 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.56, which is -99.73% below the recent high of -0.00 and -202.41% above the recent low of -1.70.

Score

Industry at a Glance

Previous score

6.52

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 196/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Aclarion Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 23.00, with a high of 23.00 and a low of 23.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

7.000

Target Price

+117.39%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Aclarion Inc

ACON

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Aclarion Inc is 1.00, ranking 381 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.71 and the support level at 2.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.031

Sell

RSI(14)

45.617

Neutral

STOCH(KDJ)(9,3,3)

41.067

Neutral

ATR(14)

0.154

Low Volatility

CCI(14)

-91.957

Neutral

Williams %R

69.767

Sell

TRIX(12,20)

-0.201

Sell

StochRSI(14)

39.316

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.182

Sell

MA10

3.204

Sell

MA20

3.308

Sell

MA50

3.307

Sell

MA100

3.529

Sell

MA200

5.398

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Aclarion Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 2.32%, representing a quarter-over-quarter increase of 45.90%. The largest institutional shareholder is The Vanguard, holding a total of 6.78K shares, representing 0.28% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

SEG Opportunity Fund LLC

244.04K

Geode Capital Management, L.L.C.

2.06K

UBS Financial Services, Inc.

1.05K

CAPTRUST Financial Advisors

10.00K

The Vanguard Group, Inc.

Star Investors

6.78K

Ness (Brent)

13.00

+333.33%

Neal (David K)

2.00

Wesemann (William G)

1.00

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aclarion Inc is 1.84, ranking 264 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.